Rivaroxaban Synthesis via Segmented Modular Steps
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing Rivaroxaban, an anticoagulant drug, are complex and lack efficient processes for producing its intermediates, which hampers scalability and production efficiency.
Innovation Solution
A method involving the reaction of compounds of Formula 8 with 5-chlorothiophene-2-carboxamide in the presence of a base, using specific reagents and conditions to produce Rivaroxaban and its intermediates, allowing for the preparation of both (R)- and (S)-enantiomers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current synthesis methods for Rivaroxaban are used, then the drug can be produced, but the synthesis process is complex and production efficiency is low
Solution Approach 1:
The patent segments the synthesis process into distinct modular steps with clearly defined intermediates (compounds of Formula I, II, III, IV, V, VI, VII, VIII). Each step uses specific reagents and conditions that can be independently optimized, allowing parallel processing and scaling of individual synthesis modules to improve overall productivity while reducing process complexity.
Solution Approach 2:
The patent employs preliminary protection group strategies (using groups such as Boc, Fmoc, Cbz, Ac) on amino and hydroxyl groups before conducting subsequent reactions. This preliminary action prevents unwanted side reactions and ensures high selectivity, thereby simplifying the overall synthesis pathway and improving production efficiency by eliminating the need for complex purification steps.
2Productivity
If current synthesis methods are used, then Rivaroxaban can be produced, but scalability is hampered
Solution Approach 1:
The patent systematically varies reaction parameters including solvent types (DCM, DMF, THF, MeCN), bases (Et3N, DIPEA, NaH, KOtBu), temperatures (-78°C to reflux), and stoichiometric ratios to optimize each synthesis step. These parameter changes enable the process to be scaled from laboratory to industrial production while maintaining consistent quality and yield, directly addressing scalability needs.
Solution Approach 2:
The patent introduces various intermediates with specific functional groups and protection strategies that facilitate smooth progression through the synthesis pathway. These intermediates serve as stable, isolable compounds that can be stored and transported, enabling modular scaling of the overall process and simplifying quality control during scale-up operations.
3Productivity
If existing synthesis processes are used, then Rivaroxaban can be manufactured, but production efficiency is reduced
Solution Approach 1:
The patent designs the synthesis route to minimize idle time between steps, with many reactions proceeding to completion in a single pot without isolation of intermediates. Continuous flow methods and telescoped reactions are employed where possible, maintaining continuous useful action throughout the synthesis process, thereby dramatically improving production efficiency and reducing overall synthesis time.
Solution Approach 2:
The patent employs periodic action through controlled addition of reagents at specific time intervals and temperatures. For example, base is added portionwise over specific time periods, and reactions are conducted at different temperature stages (initial low temperature for selectivity, then higher temperature for completion). This periodic control optimizes reaction rates and selectivity, improving production efficiency while managing synthesis time effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process simplifies the synthesis of Rivaroxaban and its intermediates, enhancing production efficiency and enabling the scalable production of both enantiomers, thereby addressing the complexity and inefficiency of existing methods.
Implementation Method 1
reacting, in the presence of a base, a compound of Formula 8 with 5-chlorothiophene-2-carboxamide of Formula 9
Data Source
AI summary
This invention provides a process for the preparation of S-Rivaroxaban and/or R- Rivaroxaban comprising reacting, in the presence of a first base, a compound of Formula (9): with a compound of Formula (8).